WuXilab WuXi peptides, primarily through its WuXi TIDES division, stands at the forefront of peptide synthesis and manufacturing, offering comprehensive CRDMO services from early-stage drug discovery through commercial production. With a strong focus on custom SPPS (Solid Phase Peptide Synthesis) services, WuXi TIDES provides efficient, flexible, and high-quality solutions for a wide range of peptide-based therapeutics2024年4月4日—WuXiSTA Launches New Small-Molecule API Facility; ExpandsPeptides, Oligonucleotides Capacity; Updates Drug-Product Expansions. Yu Lu Chief .... The company's integrated platform aims to accelerate the development of novel peptide drugs, positioning them as a key player in the evolving landscape of pharmaceutical innovation.
WuXi TIDES distinguishes itself by offering an end-to-end peptide CRDMO (Contract Research, Development, and Manufacturing Organization) platform. This encompasses everything from initial drug discovery and custom peptide synthesis to large-scale manufacturing of active pharmaceutical ingredients (APIs).WuXi peptide expansion Their capabilities extend to various peptide types, including linear, cyclic, and modified peptides, ensuring they can meet diverse project requirements. The company's commitment to rapid turnaround times, high purity standards, and robust analytical support underpins its reputation for delivering reliable peptide solutions.2023年4月6日—WuXi STA, a CRDMO, addedtwo 2,000 L reactors and a large-scale continuous purification systemfor peptide manufacturing at its Changzhou ...
The expansion of WuXi AppTec's peptide manufacturing capacity, including the addition of significant reactor volumes like two 2,000 L reactors and large-scale continuous purification systems, underscores their commitment to meeting growing global demand. These investments, seen at sites like Changzhou and Taixing, have enabled WuXi TIDES to triple its peptide manufacturing capacity, supporting numerous preclinical to commercial-stage peptide projects and producing substantial quantities of peptide APIs.作者：J Dong—Our findings suggest that AKG might serve as a therapeutic drug for the precise treatment of neurodegenerative diseases. ACS Publications. © 2026 American ... This strategic growth allows them to provide a one-stop solution for peptide conjugate discovery and development, streamlining the path to market for their partners.
WuXi TIDES is actively involved in advancing peptide-based therapeutics, exploring their potential to complement or even replace traditional approaches like antibody-based treatments in areas such as radiopharmaceuticals. Their expertise in developing complex peptide programs, such as delivering an IND-ready conjugated cyclic peptide program in a remarkably short timeframe, highlights their innovative capabilities.2023年4月6日—WuXi STA, a CRDMO, addedtwo 2,000 L reactors and a large-scale continuous purification systemfor peptide manufacturing at its Changzhou ... Furthermore, WuXi TIDES leverages advanced technologies like mRNA display for peptide discovery and screening, contributing to the identification and development of novel peptide drug candidates.
The company's integrated approach extends to peptide conjugates, offering a comprehensive platform that combines their peptide chemistry expertise with small molecule capabilities. This allows for the development of targeted peptide conjugates, a promising area for drug delivery and therapeutic intervention. By providing single-source discovery, development, and manufacturing services for these novel bioconjugates, WuXi TIDES empowers organizations to bring innovative peptide-based medicines to patients more efficiently.
WuXi AppTec's broader commitment to innovation is evident across its various divisions, including WuXi Biologics and WuXi STA2023年4月5日—With two new 2,000L reactors the total reactor volume of the Solid PhasePeptideSynthesizers atWuXiTIDES has increased to over 10,000L. April .... While WuXi TIDES focuses on oligonucleotides and peptides, these sister entities also contribute to the global open-access technology platform, driving advancements in biotechnology and pharmaceutical manufacturing. The company's continuous investment in state-of-the-art facilities and technologies, such as new peptide plants and API manufacturing facilities, reflects a dedication to maintaining high standards of quality and expanding their service offerings.2023年4月6日—WuXi STA, a CRDMO, addedtwo 2,000 L reactors and a large-scale continuous purification systemfor peptide manufacturing at its Changzhou ...
In conclusion, WuXi peptides, spearheaded by WuXi TIDES, represents a significant force in the peptide industry. Their extensive CRDMO services, coupled with a commitment to innovation and capacity expansion, positions them as a vital partner for companies seeking to develop and manufacture peptide-based therapeutics. The company's ability to handle complex projects and deliver high-quality solutions efficiently is crucial for advancing the field of peptide medicine.
Join the newsletter to receive news, updates, new products and freebies in your inbox.